{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T04:08:16Z","timestamp":1749614896104,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"DOI":"10.7759\/cureus.85689","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T10:55:57Z","timestamp":1749552957000},"source":"Crossref","is-referenced-by-count":0,"title":["Prognosis and Outcome of Carbapenem-Resistant Enterobacterales Bacteremia Managed With Ceftazidime-Avibactam and Aztreonam Combination Therapy in Tawam Hospital, UAE: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Abla","family":"Agha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Al Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Shubbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid","family":"Al Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Al Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqeel","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Geneva. WHO. (2017). https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1244482","article-title":"Carbapenem resistant Enterobacterales in the United Arab Emirates: a retrospective analysis from 2010 to 2021","volume":"11","author":"Thomsen J","year":"2023","unstructured":"Thomsen J, Abdulrazzaq NM, Everett DB, Menezes GA, Senok A, Ayoub Moubareck C. Carbapenem resistant Enterobacterales in the United Arab Emirates: a retrospective analysis from 2010 to 2021. Front Public Health. 2023, 11:1244482. 10.3389\/fpubh.2023.1244482","journal-title":"Front Public Health"},{"key":"ref3","article-title":"Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance","author":"O\u2019Neill J","year":"2016","unstructured":"O\u2019Neill J. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance. 2016."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic N","year":"2025","unstructured":"Macesic N, Uhlemann A-C, Peleg AY. Multidrug-resistant Gram-negative bacterial infections. Lancet. 2025, 405:257-72. 10.1016\/s0140-6736(24)02081-6","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-017-0191-3","article-title":"Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae","volume":"16","author":"Xu L","year":"2017","unstructured":"Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017, 16:18. 10.1186\/s12941-017-0191-3","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall S","year":"2017","unstructured":"Marshall S, Hujer AM, Rojas LJ, et al.. Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?. Antimicrob Agents Chemother. 2017, 61:10.1128\/AAC.02243-16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-lactamase-producing pathogens","volume":"33","author":"Bush K","year":"2020","unstructured":"Bush K, Bradford PA. Epidemiology of \u03b2-lactamase-producing pathogens. Clin Microbiol Rev. 2020, 33:10.1128\/CMR.00047-19","journal-title":"Clin Microbiol Rev"},{"key":"ref8","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. Atlanta, GA. CDC. (2019). https:\/\/ndc.services.cdc.gov\/wp-content\/uploads\/Antibiotic-Resistance-Threats-in-the-United-States-2019.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields RK","year":"2017","unstructured":"Shields RK, Nguyen MH, Chen L, et al.. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017, 61:10.1128\/AAC.00883-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2016.02.001","article-title":"Overview: global and local impact of antibiotic resistance","volume":"30","author":"Watkins RR","year":"2016","unstructured":"Watkins RR, Bonomo RA. Overview: global and local impact of antibiotic resistance. Infect Dis Clin North Am. 2016, 30:313-22. 10.1016\/j.idc.2016.02.001","journal-title":"Infect Dis Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv170","article-title":"Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens","volume":"70","author":"Nicolau DP","year":"2015","unstructured":"Nicolau DP, Siew L, Armstrong J, Li J, Edeki T, Learoyd M, Das S. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. J Antimicrob Chemother. 2015, 70:2862-9. 10.1093\/jac\/dkv170","journal-title":"J Antimicrob Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin D","year":"2017","unstructured":"van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2017, 8:460-9. 10.1080\/21505594.2016.1222343","journal-title":"Virulence"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw282","article-title":"The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace","volume":"215","author":"Logan LK","year":"2017","unstructured":"Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017, 215:S28-36. 10.1093\/infdis\/jiw282","journal-title":"J Infect Dis"},{"key":"ref14","article-title":"National Strategy and Action Plan for Combatting Antimicrobial Resistance (NAP-AMR)","author":"UAE Ministry of Health and Prevention","year":"2021","unstructured":"UAE Ministry of Health and Prevention. National Strategy and Action Plan for Combatting Antimicrobial Resistance (NAP-AMR). 2021."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2015.12.005","article-title":"Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review","volume":"44","author":"Tischendorf J","year":"2016","unstructured":"Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization with carbapenem-resistant Enterobactericeae: a systematic review. Am J Infect Control. 2016, 44:539-43. 10.1016\/j.ajic.2015.12.005","journal-title":"Am J Infect Control"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.06.024","article-title":"A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae","volume":"91","author":"Guti\u00e9rrez-Guti\u00e9rrez B","year":"2016","unstructured":"Guti\u00e9rrez-Guti\u00e9rrez B, Salamanca E, de Cueto M, et al.. A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae. Mayo Clin Proc. 2016, 91:1362-71. 10.1016\/j.mayocp.2016.06.024","journal-title":"Mayo Clin Proc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.08.030","article-title":"Management of KPC-producing Klebsiella pneumoniae infections","volume":"24","author":"Bassetti M","year":"2018","unstructured":"Bassetti M, Giacobbe DR, Giamarellou H, et al.. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018, 24:133-44. 10.1016\/j.cmi.2017.08.030","journal-title":"Clin Microbiol Infect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw459","article-title":"Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis","volume":"72","author":"Righi E","year":"2017","unstructured":"Righi E, Peri AM, Harris PN, Wailan AM, Liborio M, Lane SW, Paterson DL. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017, 72:668-77. 10.1093\/jac\/dkw459","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae","volume":"68","author":"Tumbarello M","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, et al.. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae. Clin Infect Dis. 2019, 68:355-64. 10.1093\/cid\/ciy492","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1255-z","article-title":"Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study","volume":"20","author":"Zander J","year":"2016","unstructured":"Zander J, D\u00f6bbeler G, Nagel D, et al.. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study. Crit Care. 2016, 20:79. 10.1186\/s13054-016-1255-z","journal-title":"Crit Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120912049","article-title":"How to manage KPC infections","volume":"7","author":"Bassetti M","year":"2020","unstructured":"Bassetti M, Peghin M. How to manage KPC infections. Ther Adv Infect Dis. 2020, 7:2049936120912049. 10.1177\/2049936120912049","journal-title":"Ther Adv Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30485-1","article-title":"Surveillance for control of antimicrobial resistance","volume":"18","author":"Tacconelli E","year":"2018","unstructured":"Tacconelli E, Sifakis F, Harbarth S, et al.. Surveillance for control of antimicrobial resistance. Lancet Infect Dis. 2018, 18:99-106. 10.1016\/S1473-3099(17)30485-1","journal-title":"Lancet Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam TF","year":"2016","unstructured":"Barlam TF, Cosgrove SE, Abbo LM, et al.. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016, 62:e51-77. 10.1093\/cid\/ciw118","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372686-prognosis-and-outcome-of-carbapenem-resistant-enterobacterales-bacteremia-managed-with-ceftazidime-avibactam-and-aztreonam-combination-therapy-in-tawam-hospital-uae-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T10:55:58Z","timestamp":1749552958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372686-prognosis-and-outcome-of-carbapenem-resistant-enterobacterales-bacteremia-managed-with-ceftazidime-avibactam-and-aztreonam-combination-therapy-in-tawam-hospital-uae-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.85689","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,10]]}}}